GENE Design Inc.

GENE Design Inc. is a Japanese biotechnology company based in Ibaraki, Japan, that operates as an oligonucleotide and peptide contract development and manufacturing organization (CDMO). Its business is presented publicly under the Ajinomoto Bio-Pharma Services oligonucleotide platform at ajioligos.com, where it markets custom DNA and RNA oligonucleotide synthesis, sgRNA synthesis services, BNA and LNA oligonucleotides, siRNA and siRNA sequence design, miRNA mimics and inhibitors, peptides, and research reagents and consumables. The company positions itself as a trusted partner for research-use oligonucleotide nucleic acids as well as for therapeutic oligonucleotide development and manufacturing. The company's service portfolio spans both research-grade products and regulated CDMO services. On the products side, it supplies DNA/RNA oligos, sgRNA, BNA/LNA oligos, siRNA, miRNA mimic and inhibitor tools, peptides, and laboratory consumables and nucleic-acid synthesis reagents. On the services side, it offers custom synthesis, siRNA sequence design, contract analysis, and platform technologies and CDMO services aimed at biotechnology and pharmaceutical companies developing nucleic-acid therapeutics. GENE Design is part of the global Ajinomoto Bio-Pharma Services network, which the company describes as having sites in Belgium, the United States, Japan, and India. This global footprint allows it to serve biotechnology and pharmaceutical customers worldwide, combining local Japanese oligonucleotide expertise with the broader manufacturing and regulatory capabilities of the Ajinomoto group. The company emphasizes customer focus, innovation, reliability, compliance, communication, and teamwork as core values, and it maintains a quality management system oriented toward nucleic-acid drug quality policies, customer audits, and inspection readiness. Its public communications include news and press releases, such as notices of summer holidays and executive personnel changes, as well as product campaigns highlighting areas like long-chain RNA synthesis. The company continues to develop its platform technologies and CDMO offerings, reflecting the growing demand for oligonucleotide-based therapeutics and research tools.

GENE Design Inc. is a Japanese biotechnology company located in Ibaraki, Japan, and is presented publicly as part of the Ajinomoto Bio-Pharma Services oligonucleotide business. Its website, ajioligos.com, operates under the Ajinomoto Bio-Pharma Services brand and describes the company's mission as contributing to people's health through oligonucleotide and peptide products and services. The company's business has developed around oligonucleotide synthesis, an area in which it presents itself as having a record of trust and achievement. Its portfolio has expanded from research-use oligonucleotide nucleic acids into a broader set of platform technologies and CDMO services. These include custom DNA and RNA oligonucleotide synthesis, sgRNA synthesis services, BNA and LNA oligonucleotides, siRNA and siRNA sequence design, miRNA mimics and inhibitors, peptides, and research consumables and nucleic-acid synthesis reagents. As part of the Ajinomoto group, GENE Design benefits from a global operating base that the company describes as spanning Belgium, the United States, Japan, and India. This network supports the delivery of solutions and services to biotechnology and pharmaceutical companies worldwide. The company emphasizes values of customer focus, innovation, reliability, compliance, communication, and teamwork, and it maintains a quality management system that undergoes regular review, trend analysis, and process optimization, with readiness for customer audits and regulatory inspections. In recent years the company has continued to promote its platform technologies and CDMO services, including areas such as long-chain RNA synthesis, and it communicates with customers and stakeholders through news and press releases covering operational notices and executive personnel changes. Its ongoing development reflects the broader growth of the oligonucleotide therapeutics field and the demand for reliable synthesis and manufacturing partners.

• Company operates as an oligonucleotide and peptide CDMO based in Ibaraki, Japan, presented under the Ajinomoto Bio-Pharma Services oligonucleotide platform.

• Public website ajioligos.com markets DNA/RNA oligo synthesis, sgRNA CDMO services, siRNA and siRNA sequence design, BNA & LNA oligos, miRNA mimic & inhibitor, peptides, and research consumables.

• Press release announcing executive personnel changes.

• News notice regarding summer holidays.

Trusted Japanese oligonucleotide and peptide CDMO within the global Ajinomoto Bio-Pharma Services network, serving biotechnology and pharmaceutical customers with research products and therapeutic nucleic-acid development and manufacturing services.

• DNA/RNA oligonucleotides

  Custom DNA and RNA oligonucleotide synthesis.

• sgRNA synthesis services

  sgRNA synthesis offered as a CDMO service.

• BNA & LNA oligonucleotides

  Bridged and locked nucleic acid oligonucleotide products.

• siRNA and siRNA sequence design

  siRNA products and sequence design services.

• miRNA mimic & inhibitor

  miRNA mimic and inhibitor research tools.

• Peptides

  Peptide products and services.

• Research consumables and nucleic-acid synthesis reagents

  Laboratory consumables and reagents for nucleic-acid synthesis.

1. 1Aji Bio-Pharma Oligos | Homeajioligos.com
2. 2Aji Bio-Pharma Oligos | Overview: About - Japaneseajioligos.com
3. 3Aji Bio-Pharma Oligos | Peptides - Japaneseajioligos.com
4. 4Aji Bio-Pharma Oligos | Overview - Japaneseajioligos.com
5. 5GENE Design Inc. (Japan) - Wikidatawikidata.org